These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 19655244)

  • 1. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
    Khan QJ; Reddy PS; Kimler BF; Sharma P; Baxa SE; O'Dea AP; Klemp JR; Fabian CJ
    Breast Cancer Res Treat; 2010 Jan; 119(1):111-8. PubMed ID: 19655244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
    Khan QJ; Kimler BF; Reddy PS; Sharma P; Klemp JR; Nydegger JL; Yeh HW; Fabian CJ
    Breast Cancer Res Treat; 2017 Nov; 166(2):491-500. PubMed ID: 28770449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole.
    Arul Vijaya Vani S; Ananthanarayanan PH; Kadambari D; Harichandrakumar KT; Niranjjan R; Nandeesha H
    Clin Chim Acta; 2016 Aug; 459():53-56. PubMed ID: 27221206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
    Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
    Singh S; Cuzick J; Mesher D; Richmond B; Howell A
    Breast Cancer Res Treat; 2012 Apr; 132(2):625-9. PubMed ID: 22198469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
    Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
    Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
    Prieto-Alhambra D; Javaid MK; Servitja S; Arden NK; Martinez-García M; Diez-Perez A; Albanell J; Tusquets I; Nogues X
    Breast Cancer Res Treat; 2011 Feb; 125(3):869-78. PubMed ID: 20665105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
    Niravath P; Hilsenbeck SG; Wang T; Jiralerspong S; Nangia J; Pavlick A; Ademuyiwa F; Frith A; Ma C; Park H; Rigden C; Suresh R; Ellis M; Kent Osborne C; Rimawi MF
    Breast Cancer Res Treat; 2019 Sep; 177(2):427-435. PubMed ID: 31218477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D insufficiency: evaluation of an oral standardized supplementation using 100,000 IU vials of cholecalciferol, depending on initial serum level of 25OH vitamin D.
    Rouillon V; Dubourg G; Gauvain JB; Baron D; Glemarec J; Cormier G; Guillot P
    Joint Bone Spine; 2012 Jul; 79(4):399-402. PubMed ID: 22056759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
    Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
    Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy.
    Crew KD; Shane E; Cremers S; McMahon DJ; Irani D; Hershman DL
    J Clin Oncol; 2009 May; 27(13):2151-6. PubMed ID: 19349547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
    Singer O; Cigler T; Moore AB; Levine AB; Do HT; Mandl LA
    Breast J; 2014; 20(2):174-9. PubMed ID: 24467395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of various vitamin D supplementation regimens in breast cancer patients.
    Peppone LJ; Huston AJ; Reid ME; Rosier RN; Zakharia Y; Trump DL; Mustian KM; Janelsins MC; Purnell JQ; Morrow GR
    Breast Cancer Res Treat; 2011 May; 127(1):171-7. PubMed ID: 21384167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
    Wasan KM; Goss PE; Pritchard PH; Shepherd L; Palmer MJ; Liu S; Tu D; Ingle JN; Heath M; Deangelis D; Perez EA
    Ann Oncol; 2005 May; 16(5):707-15. PubMed ID: 15817595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Supplementation of Parturient Mothers with Vitamin D and Its Effect on 25OHD Status of Exclusively Breastfed Infants at 6 Months of Age: A Double-Blind Randomized Placebo Controlled Trial.
    Naik P; Faridi MMA; Batra P; Madhu SV
    Breastfeed Med; 2017 Dec; 12(10):621-628. PubMed ID: 29027817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.